Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Completed

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.

Key facts

Study ID

NCT02154672

Run by

Yale University

People needed

1

Starts

2014-05-01

Expected to finish

2019-11-01

Last updated by the study team

2021-02-09

Who can join

Age: 30 and older, up to 90. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• All men ≥30 years of age with at least a ten-year life expectancy
• A known BRCA2 mutation
• Ability to have an MRI
• Able to give informed consent will be approached to participate in the study

You may not qualify if…

• If a man has received or is currently receiving treatment for prostate cancer

Where it is running

• Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.